You are here
Notice of Extraordinary General Meeting
4 June 2008: Notice of extraordinary general meeting is enclosed. The general meeting is scheduled for June 18 2008, 10:00 am, and will take place at the company`s office, Frysjaveien 40, Oslo.
In the meeting, it will be proposed to increase the company`s share capital with minimum NOK 1,500,000 and maximum NOK 2,500,245.70 by issuance of minimum 15,000,000 and maximum 25,002,457 shares with nominal value NOK 0.10. The registered shareholders as of June 18 will have a pre-emptive right to subscribe for and be allotted new shares.
The subscription price is proposed to NOK 2.00 per new share. The minimum of 15,000,000 new shares have been underwritten by an underwriting syndicate established by Pareto Private Equity AS. The subscription period for the new shares will be from 26 June 2008 to 9 July 2008.
The net proceeds from the offering will strengthen the company`s financial position, and secure necessary working capital for the completion of the various development programs in the cancer business as well as the infectious diseases business.
Additionally, the board will propose for the general meeting to confirm a strike price equal to the subscription price in the rights
offering (NOK 2.00) for the shares in the previously decided option scheme for employees.
Contact: CEO Mårten Wigstøl Phone: +47 911 65775
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 36 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com
Link OSE Newsweb and the Notice to the Extraordinary General Meeting